CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

is pending final approval by the director of the CDC and the Department of Health and Human Services. Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and ...

HHS: Kennedy says he is not opposed to vaccination, but described them as a personal choice in the midst of a large U.S.

GSK claims that Pfizer’s FDA-approved vaccine for respiratory syncytial virus infringes on four patents protecting its own approved vaccine, Arexvy. The patent suit comes with the RSV season ...

has issued new separate recommendations supporting expanded use of Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, and GSK’s Penmenvy (meningococcal groups A, B, C, W, and Y Vaccine), a ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled trials before they’re licensed for use, raising urgent questions about the ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE ... its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV ...